GUANGJI PHARMA released its performance for the first three quarters, with a net loss attributable to the parent company of 97.3 million yuan
According to the Zhitong Finance APP, GUANGJI PHARMA disclosed its third-quarter report for 2025. The company achieved revenue of 429 million yuan in the first three quarters, a year-on-year decrease of 7.12%; the net profit attributable to the parent company was a loss of 97.3 million yuan; the net profit excluding non-recurring gains and losses was a loss of 101 million yuan; basic earnings per share were -0.2789 yuan
According to the Zhitong Finance APP, GUANGJI PHARMA (000952.SZ) disclosed its third-quarter report for 2025. The company achieved a revenue of 429 million yuan in the first three quarters, a year-on-year decrease of 7.12%; the net profit attributable to shareholders was a loss of 97.3 million yuan; the net profit excluding non-recurring gains and losses was a loss of 101 million yuan; the basic earnings per share were -0.2789 yuan
